CCORF Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $8
Morgan Stanley Maintains LifeStance Health(LFST.US) With Buy Rating, Maintains Target Price $10
Lifestance Health Group (LFST) Gets a Buy From Morgan Stanley
LifeStance Health Group Inc (LFST) Q1 2025 Earnings Call Highlights: A Promising Start With ...
LifeStance Health | 10-Q: Q1 2025 Earnings Report
William Blair Maintains LifeStance Health(LFST.US) With Buy Rating
LifeStance Health | 8-K: LifeStance Reports First Quarter 2025 Results
NVA Appoints Ken Burdick Executive Chairman Ahead of Future IPO
Lifestance Health Down Over 16%, on Pace for Largest Percent Decrease in Almost a Year -- Data Talk
Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NVO) and Lifestance Health Group (LFST)
LifeStance Health Group GAAP EPS of $0.00, Revenue of $333M
LifeStance Health Group Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Sales Results.
Lifestance Health Group's Q1 Earnings, Revenue Rise; Reiterates 2025 Revenue Guidance
Express News | Lifestance Health Shares up 8.4% Premarket After Q1 Rev Beat
LifeStance Health Reports First Positive Net Income
Earnings Flash (LFST) Lifestance Health Group Breaks Even in Q1, Vs. FactSet Est of $0.04 Loss
Express News | Lifestance Health Group Inc: For FY 2025, Reiterating Expectations for Rev of $1.40 Bln to $1.44 Bln
Express News | Lifestance Reports First Quarter 2025 Results
Express News | Lifestance Health Q1 Adjusted Ebitda USD 34.6 Million Vs. IBES Estimate USD 30.2 Million
Express News | Lifestance Health Outlook Q2 Revenue USD 332-352 Million